A simplified HAART regimen with lopinavir/ritonavir in HIV infected patients commencing treatment for concurrent hepatitis C infection.

Trial Profile

A simplified HAART regimen with lopinavir/ritonavir in HIV infected patients commencing treatment for concurrent hepatitis C infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2011

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C; HIV infections
  • Focus Adverse reactions
  • Acronyms KAMON-2
  • Most Recent Events

    • 11 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top